Enochian Pre-IND Request for Potential Cure for Hepatitis B Virus Infection Accepted by FDA

By Robb M. Stewart

Enochian BioSciences Inc. pre-investigational new drug request for a potential cure of hepatitis B virus infection has been accepted by the U.S. Food and Drug Administration.

Written comments are expected this fall, the company said Monday.

In premarket trading, its shares were 8% higher after ending last Friday at $5.26, up 78% so far in 2021 and 34% over the past 12 months.

Enochian said its pre-investigational new drug request was made based on promising data from a proof-of-concept study conducted in chimeric mice, an animal model to evaluate a HBV cure.

Write to Robb M. Stewart at [e-mail]

(END) Dow Jones Newswires

07-12-21 0739ET